These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 11688111)

  • 1. Managed care trends in statin usage.
    Bazalo GR
    Manag Care; 2001 Oct; 10(10):48-50, 53-9. PubMed ID: 11688111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of diagnostic cluster methodology for therapeutic costing and drug surveillance of HMG-CoA reductase-inhibitor therapy.
    Bottorff MB; Yenkowsky JP; Cave DG
    Clin Ther; 1999 Jan; 21(1):218-35. PubMed ID: 10090437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD; Rattinger GB; Kuznik A; Koren MJ
    Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
    Cobos A; Jovell AJ; García-Altés A; García-Closas R; Serra-Majem L
    Clin Ther; 1999 Nov; 21(11):1924-36. PubMed ID: 10890264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels.
    Maclaine GD; Patel H
    Int J Clin Pract; 2001 May; 55(4):243-9. PubMed ID: 11406909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Which statin is more efficient? Concepts and applications in economic evaluation].
    García-Altés A; Jovell AJ
    Aten Primaria; 2000 Sep; 26(5):333-8. PubMed ID: 11100606
    [No Abstract]   [Full Text] [Related]  

  • 9. Effective use of statins to prevent coronary heart disease.
    Crouch MA
    Am Fam Physician; 2001 Jan; 63(2):309-20, 323-4. PubMed ID: 11201696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
    Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
    Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
    Jones P; Kafonek S; Laurora I; Hunninghake D
    Am J Cardiol; 1998 Mar; 81(5):582-7. PubMed ID: 9514454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin.
    Koren MJ; Smith DG; Hunninghake DB; Davidson MH; McKenney JM; Weiss SR; Schrott HG; Henley RW; Tresh P; McLain RW; Bakker-Arkema RG; Black DM
    Pharmacoeconomics; 1998 Jul; 14(1):59-70. PubMed ID: 10182195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada.
    Austin PC; Mamdani MM
    Circulation; 2005 Aug; 112(9):1296-300. PubMed ID: 16116054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of atorvastatin over the product life cycle in the United States.
    Grabner M; Johnson W; Abdulhalim AM; Kuznik A; Mullins CD
    Clin Ther; 2011 Oct; 33(10):1433-43. PubMed ID: 21955936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of statin withdrawal on frequency of cardiac events after vascular surgery.
    Schouten O; Hoeks SE; Welten GM; Davignon J; Kastelein JJ; Vidakovic R; Feringa HH; Dunkelgrun M; van Domburg RT; Bax JJ; Poldermans D
    Am J Cardiol; 2007 Jul; 100(2):316-20. PubMed ID: 17631090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic dose assessment of patient switching from atorvastatin to simvastatin.
    Hess G; Sanders KN; Hill J; Liu LZ
    Am J Manag Care; 2007 Jun; 13 Suppl 3():S80-5. PubMed ID: 17596116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
    Hirsch M; O'Donnell JC; Jones P
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):18-28. PubMed ID: 15703502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
    Lindgren P; Graff J; Olsson AG; Pedersen TJ; Jönsson B;
    Eur Heart J; 2007 Jun; 28(12):1448-53. PubMed ID: 17371782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
    Tran YB; Frial T; Miller PS
    Can J Clin Pharmacol; 2007; 14(2):e205-14. PubMed ID: 17556788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.